Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 4/20 | 0.46 |
| ▸ | RAB9A | P51151 | 4/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.46 |
| ▸ | RPS6KA2 | Q15349 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | MITF | O75030 | 1/20 | 0.46 |
| ▸ | XBP1 | P17861 | 1/20 | 0.46 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.46 |
| ▸ | KLF5 | Q13887 | 1/20 | 0.46 |
| ▸ | MAPKAPK2 | P49137 | 2/20 | 0.45 |
| ▸ | TRPV1 | Q8NER1 | 9/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2994985 | 0.82 | KDR (0.52) | KDRNPC1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL3001660 | 0.78 | MAPKAPK2 (0.71) | KDRNPC1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL2996330 | 0.73 | MAPKAPK2 (0.58) | KDRNPC1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL2996321 | 0.73 | MAPKAPK2 (0.50) | KDRNPC1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL3001283 | 0.72 | MAPKAPK2 (0.73) | MAPKAPK2 | |
| SCHEMBL846669 | 0.68 | TRPV1 (0.58) | KDRNPC1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL4935881 | 0.68 | KDR (0.64) | KDRNPC1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL846408 | 0.67 | KDR (0.64) | KDRNPC1RAB9ASMN1; SMN2RPS6KA3 | |
| SCHEMBL845978 | 0.67 | KDR (0.79) | KDRNPC1RAB9ASMN1; SMN2KDM4E | |
| SCHEMBL847442 | 0.67 | KDR (0.66) | KDRNPC1RAB9ASMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100190773-A1 | Anti-Cytokine Heterocyclic Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100190773-A1 | Anti-Cytokine Heterocyclic Compounds | MAPKAPK2, MAP4K2, MAP3K2 | KDR 2519/4885NPC1 4214/4885RAB9A 1982/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.